Professor Pär Nordlund, co-founder of Sprint Bioscience, publish the first scientific paper describing CETSA (Cellular Thermal Shift Assay), which utilize the concept that target proteins usually get stabilized when drug molecules bind. CETSA is a method that can directly measure whether drug molecules bind to their targets in vivo. The method works on a wide variety of target proteins and allows scientists to directly measure whether a drug molecule reach its targets in cells and animal models. The method, which is described in the scientific journal Science, could make a significant contribution to the development of new, improved drug substances.
